Article Text

Download PDFPDF

Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab
  1. Norihiro Nishimoto1,
  2. Jun Hashimoto1,
  3. Nobuyuki Miyasaka2,
  4. Kazuhiko Yamamoto3,
  5. Shinichi Kawai4,
  6. Tsutomu Takeuchi5,
  7. Norikazu Murata6,
  8. Désirée van der Heijde7,
  9. Tadamitsu Kishimoto1
  1. 1Osaka University, Osaka, Japan
  2. 2Tokyo Medical & Dental University, Tokyo, Japan
  3. 3University of Tokyo, Tokyo, Japan
  4. 4Toho University Omori Medical Center, Tokyo, Japan
  5. 5Saitama Medical Center/School, Saitama, Japan
  6. 6Kyowakai Hospital, Osaka, Japan
  7. 7University Hospital Maastricht, Maastricht, The Netherlands
  1. Correspondence to:
    Norihiro Nishimoto
    MD, Laboratory of Immune Regulation, Graduate School of Frontier Biosciences, Osaka University 1–3, Yamada-oka, Suita, Osaka, 565-0871, Japan; norihiro{at}fbs.osaka-u.ac.jp

Footnotes

  • Published Online First 8 June 2007

  • Competing interests: NN has served as a consultant to and/or received honoraria from Chugai Pharmaceutical, the manufacture of tocilizumab. TK holds a patent for tocilizumab. The other authors have no competing interests.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Published Online First 8 June 2007

  • Competing interests: NN has served as a consultant to and/or received honoraria from Chugai Pharmaceutical, the manufacture of tocilizumab. TK holds a patent for tocilizumab. The other authors have no competing interests.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.